This positioning suggests that apoB may serve as a clinically meaningful biomarker for risk stratification, bridging the gap between high-risk thresholds established by ADA/ACC and moderate-risk thresholds outlined in ATP III, as both of them have two or more risk factors with no previous history of diabetes or CAD. The gene discussed is APOB; the disease is diabetes mellitus.